Although BRAF inhibitors alone have been shown to induce metastasis in RAS-mutant melanomas by increasing ERK phosphorylation due to the so-called paradoxical activation of wild-type BRAF, a recent study was able to demonstrate that this effect could be reversed by a combination with an MEK inhibitor [21,30]. Here, BRAF is linked to melanoma.